About IJDRA Journal
International Journal of Drug Regulatory Affairs: (IJDRA) is a Quarterly open access Journal aimed at everyone working for Regulatory Affairs, Intellectual Property Rights and Pharmaceutical development. IJDRA was first Journal in Regulatory Affairs in India started in May, 2013 to provide the quality information on the latest updates on Drug regulation in pharmaceutical industry. In addition to the highest-quality reviews, each issue includes concise updates on the latest advances in areas such Regulatory Affairs, Pharmaceutical development and emerging industry trends and strategies.
IJDRA is fulfilling the requirements of readers, Regulatory & Pharmacy professionals. It covers subjects as:
- Drug Regulatory Affairs (Pharmaceuticals, Medical Device, Biologicals, Active Substance, Natural products, Agrochemicals, Food, and Veterinary)
- Intellectual Property Rights
- Pharmaceutical Development
- Pharmacology & Toxicology
- Clinical study & Bioequivalence
The correct abbreviation for abstracting and indexing purposes is “Int. J. Drug Regul. Aff”.
The international standard serial numbers (ISSN) for International Journal of Drug Regulatory Affairs are 2321-7162 (print) and 2321-6794 (online).
International Journal of Drug Regulatory Affairs (IJDRA) has Publication frequency quarterly (4 Issue/Year). We always publish every issue timely since starting of this Journal. Issue schedule is 15-March, 15-June, 15-September and 15-December in every year for Issue 1, 2, 3, and 4 respectively.
See all indexing in Indexing page.
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
International Journal of Drug Regulatory Affairs actively supports the Archiving process, and continually works with authors, readers, subscribers and site-license holders to develop its policy.
IJDRA Journal utilizes the SHERPA/ROMEO and Copernicus Index to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration.
International Journal of Drug Regulatory Affairs works on OJS/PKP platform and provides interface for metadata harvesting and XML for Articles & Issues.
Open Journal Systems (OJS) is a journal management and publishing system that has been developed by the Public Knowledge Project through its federally funded efforts to expand and improve access to research.
OJS assists with every stage of the refereed publishing process, from submissions through to online publication and indexing. Through its management systems, its finely grained indexing of research, and the context it provides for research, OJS seeks to improve both the scholarly and public quality of refereed research.
Click here to find out what's on the Regulatory Affairs & Drug development conference circuit and which meetings will be attended by the editors of International Journal of Drug Regulatory Affairs.
International Journal of Drug Regulatory Affairs has no external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors, who are M.Pharm & PhD-level scientists & expert in their area of specialization.
Information on Journal staff.
In deciding what to include, we surveyed authors, readers and librarians to determine which metrics were important to their decision-making. We will continue to review and shape our provision of data going forward.
This page provides information on peer review performance and citation metrics for the International Journal of Drug Regulatory Affairs. Data are collected annually for full calendar years.2017 Peer Review Metrics
Submission to first editorial decision: the median time (in days) from when a complete submission is received to when a first editorial decision about whether the paper was sent out for formal review or not is sent to the authors.
Submission to first post-review decision: for manuscripts that are sent to external reviewers, the median time (in days) taken from when a complete submission is received to when a editorial decision post-review is sent to the authors.
Submission to Accept: the median time (in days) from the published submission date to the final editorial acceptance date; submission date corresponds to the date of receipt of the version of the paper that received an editorial decision to revise and resubmit.
Submission to first editorial decision (median, days)
Submission to first post-review decision (median, days)
Submission to Accept (median, days)
General editorial inquiries and correspondence should be addressed to the Editor, at firstname.lastname@example.org.
Inquiries about the status of a manuscript should be addressed to the Editorial Assistant, email@example.com.
To inquire about institutional access, advertising or marketing, visit the Media partner for further contact information.